linjc16/ctgov huggingface dataset:
The Effect of Ground and Unground Enamel on the Clinical Performance of Direct Composite Build-ups

Study Overview
=================
Brief Summary
-----------------
Twenty-four patients participated in the study. Patients received direct composite build-ups for diastema closure.

Detailed Description
-----------------
The restorations were performed separately by grounding and ungrounding the enamel on the proximal surfaces in symmetrical teeth.

Official Title
-----------------
The Effect of Ground and Unground Enamel on the Clinical Performance of Direct Composite Build-ups After Orthodontic Treatment: Five Years of Follow-up

Conditions
-----------------
Trial of Labor; Failure

Intervention / Treatment
-----------------
* Other: Direct composite build-ups


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good oral hygiene, no periodontal or pulpal disease, interarch tooth size discrepancies (Bolton discrepancy) after orthodontic treatment Exclusion Criteria: uncontrollable parafunctions, insufficient or poor oral hygiene, periodontal or gingival disease

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>Restoration | Other: Direct composite build-ups<br>* Direct composite build-ups application<br>|
| Experimental: Arm 2<br>Evaluate | Other: Direct composite build-ups<br>* Direct composite build-ups application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate |  | 5 years |
Blood Ammonia as Predictor for Esophageal Varices and Risk of Bleeding

Study Overview
=================
Brief Summary
-----------------
Assessment of blood ammonia level as a non-invasive predictor for presence of EV and risk of bleeding

Detailed Description
-----------------
A prospective cross sectional study on 150 consecutive patients screening for esophageal varices. Patient groups groups: Group (1): 100 patients with esophageal varices Group (2): 50 chronic liver disease patients with no esophageal varices as a control group. All patients will be subjected to: - Detailed history-taking - Full clinical examination - Laboratory investigations: Complete blood picture (CBC) Erythrocyte sedimentation rate (ESR) Renal function tests Liver function tests Prothrombin time and activity Viral markers (HCV Ab - HBV Ag) Blood ammonia level. - Pelviabdominal US: Ultrasound examination of the liver, portal venous system, spleen, kidney and other abdominal organs. - Upper GITendoscopy: Varices will be classified according to the Japanese classification 1996, The Baveno 11 score will be used to differentiate between mild and severe portal hypertensive gastropathy.

Official Title
-----------------
Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding

Conditions
-----------------
Chronic Liver Disease, Esophageal Varices

Intervention / Treatment
-----------------
* Diagnostic Test: Endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with chronic liver disease Exclusion Criteria: Patient in hepatic encephalopathy or coma. Patient in active bleeding or with history of bleeding within the two weeks prior to entry in the study . Patients with heart failure. Patients with renal failure. Patient with hepatocellular carcinoma and portal vein thrombosis. Patient taking Beta blockers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Endoscopy<br> | Diagnostic Test: Endoscopy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of serum ammonia in patients with risk factors for bleeding from esophageal varices | estimation of level of serum ammonia in patients with risk factors for bleeding from esophageal varices | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ammonia, bleeding risk factors, endoscopic risk signs for bleeding, esophageal varices
Observational Study of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to observe change of distribution pattern of Hunner's ulcer in patient with interstitial cystitis/bladder pain syndrome

Detailed Description
-----------------
This is observational, 12 months study

Official Title
-----------------
Longitudinal Change of Distribution Pattern of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome

Conditions
-----------------
Interstitial Cystitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study Pain VAS ≥4 O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2) PUF score ≥ 13 cystoscopic record within 2 years Hunner ulcer lesion in cystoscopic finding Exclusion Criteria: Scheduled for or use of intravesical therapy (eg, bladder distention,transurethral resection of bladder ulcer, instillation) during or within 6months prior to the study and use of pentosan polysulfate sodium within 1 months prior to the study Patients who are pregnancy or, childbearing age without no contraception Patients with voided volume <40 or, > 400ml Patients with microscopic hematuria, (≥1+ in dipstick), If not excluded that no evidence of neoplastic tumor examination Patients with urine culture showing evidence of urinary tract infection 1month prior to the study Accompanied medical problem below Tuberculosis in urinary system Bladder cancer, urethral cancer, prostate cancer Recurrent cystitis Anatomical disorder Patients had prior surgery (eq, bladder augmentation, cystectomy Patients with neurologic disorder Patients with indwelling catheter or intermittent self-catheterization Patients with psychologic problem

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hunner's ulcer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of distribution pattern of Hunner's ulcer |  | 1 month, 6month, 12month |
Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes

Study Overview
=================
Brief Summary
-----------------
The objective of this common multicenter protocol is to test the hypothesis that algorithmic tools using clinical Neonatal Intensive Care Unit (NICU) cardiorespiratory monitoring data can detect ventilatory control instability and predict chronic and acute respiratory consequences of ventilatory control instability and autonomic dysregulation.

Official Title
-----------------
Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes

Conditions
-----------------
Infant, Premature

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonatal Intensive Care Unit patient on cardiorespiratory monitor which has been configured to collect data to store for this study < 29 wks Gestational Age < 1 wk Chronological Exclusion Criteria: Unlikely to survive or decision not to pursue full care Major congenital or chromosomal anomaly

Ages Eligible for Study
-----------------
Maximum Age: 1 Week

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Outcome | Favorable: Either (1) an inpatient at 40 weeks post-menstrual age and not on oxygen, nor on other flow/pressure respiratory support, nor on inhaled/oral/IV respiratory medications, OR (2) discharged prior to 40 weeks post-menstrual age not on respiratory meds, oxygen, or other respiratory support. Unfavorable: Either (1) Deceased at 40 weeks , (2) inpatient on meds/O2/support at 40 weeks post-menstrual age, or (3) previously discharged prior to 40 weeks on meds/O2/support | 40 weeks post-menstrual age. | 
| Physiological Outcome | Reported Value will be the percentile value of scores, as plotted on a standard curve of scores for peers. The score is calculated by aggregating the following measurements: Periodic Breathing Percentage (%) Number of Apnea events (#) Number of Bradycardia events (#) Number of Desaturation events (#) Number of combined events (example Apnea with Bradycardia and Desaturation (#) | 36 weeks and 1 day to 37 weeks and 0 days, post-menstrual age | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time on respiratory support and medications |  | before 52 weeks post-menstrual age | 
| chronic lung disease |  | before 52 weeks post-menstrual age | 
| pulmonary hypertension |  | before 52 weeks post-menstrual age | 
| sepsis |  | before 52 weeks post-menstrual age | 
| necrotizing enterocolitis |  | before 52 weeks post-menstrual age |
Indwelling Stent Discoloration Project

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to identify the root cause for the significant discolouration of Boston Scientific Percuflex based stents.

Detailed Description
-----------------
The aim of this study is to identify the root cause for the significant discolouration of Boston Scientific Percuflex based stents observed in some patients, particularly those from Japan. We will also test and compare them to stents from Canadian patients. Furthermore, we will determine whether the discolouration promotes bacterial adhesion and/or encrustation of the stent.

Official Title
-----------------
Examining the Underlying Factors That Cause Ureteral Stent Discoloration in Japanese and Canadian Ureteral Stents

Conditions
-----------------
Urologic Injuries, Disorder of Urinary Stent, Kidney Calculi, Urinary Tract Obstruction Due to Specified Cause, Hydronephrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 19 years of age (Vancouver, British Columbia, Canada - for Japan different age limit as applicable) Patient has indwelling ureteral stent Exclusion Criteria: Pregnancy Positive Urine Culture Active cancer Recurrent urinary infections Gross hematuria Inability to provide informed consent Physician/Surgeon refuses to enter patient into study

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with indwelling ureteral stent<br>Patients with existing indwelling ureteral stent, no additional treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stent encrustation | Conditioning film components and encrustation | at stent removal | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| characterize the components that discolour the Percuflex material |  | bench top testing of stents | 
| Bacterial Adhesion, Colonization, and Biofilm formation | Stent pieces from the stent that has been in the patient will be exposed to bacteria and artificial urine to mimic ureter environment in order to find information on: bacterial adhesion, colonization and biofilm formation | at 4, 24, and 48 hours post stent removal | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urological problems, indwelling urologic stent, kidney stone disease, urinary system obstruction, hydronephrosis, ureteral damage
Bright Light as a Countermeasure for Circadian Desynchrony

Study Overview
=================
Brief Summary
-----------------
Light is the primary means by which the internal circadian clock remains aligned (entrained) with the external world. Misalignment of this internal clock can occur during situations such as shift work and jet travel across multiple time zones (jet lag). The purpose of this study is to examine how sequences of brief flashes of light can affect entrainment of the clock.

Official Title
-----------------
Bright Light as a Countermeasure for Circadian Desynchrony

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Bright light


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good health Normal hearing Exclusion Criteria: Sleep disorder Extreme chronotype Regular smoker Depression Alcohol abuse Illegal drug use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Light<br>Sequence of bright light flashes of varying durations, interflash intervals, flash lengths, flash brightness, and flash color. | Other: Bright light<br>* Light is administered through a custom designed mask with LED lights.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circadian phase | The timing of the onset of melatonin is compared before and after a light stimulus | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alertness | Alertness as assessed through change in brain wave (electroencephalographic, EEG) activity, questionnaires, and objective testing is examined before and at the end of a light stimulus | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy controls
Critical Incident During Anaesthesia

Study Overview
=================
Brief Summary
-----------------
A multicenter study in Ukrainian hospitals on compliance with the requirements for responding to critical cases in the operating room, and the availability of relevant documentation and checklists.

Detailed Description
-----------------
Timely information and response to emergencies are important both in the context of patient safety and in the context of the hospital economy. The availability of information systems is one of the security requirements of the Helsinki Declaration of Patient Safety. Ukraine has only just begun its path to implementing the Declaration of Helsinki in Ukrainian hospitals. The level of adherence to the recommendations can vary considerably depending on the region, the provision of the hospital and the effectiveness of the institution's internal management. In our survey of Ukrainian hospitals, only 74% of hospitals kept records of anaesthesia complications in general, with only 46% having separate electronic or paper documents to record complications; Also, the majority of respondent physicians (62.9%) reported the absence of checklists or algorithms for actions in case of emergencies or emergencies during anaesthesia.

Official Title
-----------------
Critical Incident During Anaesthesia

Conditions
-----------------
Critical Incident, Safety Issues

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: critical incident during anaesthesia: massive hemorrhage >1000ml, difficult intubation, severe hypotension, severe bradycardia, desaturation, cardiac arrest, high spinal block, anesthetic toxicity, miocardial ischemia, severe arhytmia etc Exclusion Criteria: critical incidents without aneasthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Critical Incident During Anaesthesia | Critical Incident During Anaesthesia | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The use of the WHO Safe Surgery checklist | The use of the WHO Safe Surgery checklist | 5 months | 
| Keeping records of the critical incidents | Keeping records of the critical incidents during anaesthesia | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patient safety, critical incident, anaesthesia
Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess effects of Docosahexaenoic Acid (DHA) as an add-on novel supplement on quality of life, cognitive function, craving and psychosocial factors in heavy cigarette smokers. In humans, no previous randomized, double blind controlled study has been conducted to evaluate these effects. The aim of the study is to 1. Test Docosahexaenoic Acid (DHA) beneficial effects on objective clinical indicators of cognitive function (choice reaction time, decision making, impulsivity, facial recognition) in smokers 2. Improvement of quality of life, cigarette craving, psychosocial factors and self-perceptions in smokers treated with DHA supplement

Conditions
-----------------
HEAVY TOBACCO SMOKERS

Intervention / Treatment
-----------------
* Dietary Supplement: DHA
* Dietary Supplement: Oral ingestion of 5 placebo tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nicotine dependence Smoked at least 10 cigarettes per day for the past 12 months and not interested in quitting Exclusion Criteria: Serious kidney, lun, neurological and cardiovascular diseases Suicide risk, acute psychosis, severe depression, organic brain syndromes Dependence on psychoactive substances other than nicotine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: I. DHA<br>Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel). | Dietary Supplement: DHA<br>* DHA ingested orally by heavy smokers<br>|
| Placebo Comparator: II. Placebo<br>Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel | Dietary Supplement: Oral ingestion of 5 placebo tablets<br>* Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in smoking urges and craving | Reduction in smoking urges and craving to be measured by the following: smoking urges and craving scales; choice reaction time, impulsivity computerized test, quality of life questionnaire, depression inventory, general health questionnaire, scale of perceived social support, facial expression task, self-esteem diary | One and a half years |
Clinical Profile of Parkinson's Disease in Patients With Hepatitis C Infection

Study Overview
=================
Brief Summary
-----------------
There is association between Hepatitis C and Parkinson's Disease as shown from previous studies. The clinical profile and natural history is not fully studied yet. We aim at studying the clinical characteristics of Parkinson's Disease in patients with hepatitis C infection.

Official Title
-----------------
Clinical Profile of Parkinson's Disease in Patients With Hepatitis C Infection

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with history of Parkinson's Disease and Hepatitis C infection. Exclusion Criteria: Advanced liver cirrhosis. Patients with hepatic failure. Symptoms of Parkinson's plus syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of UPDRS | Severity of Motor and non motor symptoms | 2 years |